| CAS Number | 50-78-2 |
|---|---|
| Molecular Formula | C9H8O4 |
| Molecular Weight | 180.16 |
| Pharmacopoeia | USP, EP, CP |
| Packaging | 25 KG/DRUM |
Acetylsalicylic acid was first synthesized in a pure and stable form by Felix Hoffmann at Bayer in 1897, building on centuries of traditional use of willow bark (which contains the prodrug salicin). Bayer launched it as Aspirin in 1899, and it remains one of the most widely consumed medications globally — with over 40,000 metric tons produced annually as of 2025. The compound's mechanism was not elucidated until 1971, when John Vane discovered that it works by irreversibly inhibiting cyclooxygenase (COX-1 and COX-2), a finding that earned him the 1982 Nobel Prize in Physiology or Medicine.
Unlike most NSAIDs, aspirin's irreversible acetylation of COX-1 in platelets produces a lasting antiplatelet effect that persists for the platelet's entire 7-10 day lifespan. This unique property makes low-dose aspirin (75-100 mg) a cornerstone of cardiovascular disease prevention, reducing the risk of recurrent myocardial infarction and ischemic stroke. No other NSAID shares this irreversible, long-duration antiplatelet mechanism.
The dual-dose utility of aspirin API — high-dose (300-1000 mg) for analgesia and inflammation, low-dose for antiplatelet therapy — makes it one of the most versatile bulk APIs in pharmaceutical manufacturing. It serves as the active ingredient in tablets, effervescent powders, enteric-coated formulations, and fixed-dose combinations. The compound is also the starting material for derivatives such as diflunisal and the prodrug benorylate.
As of mid-2026, global aspirin API production is concentrated in China, which accounts for an estimated 60-70% of worldwide output, with key manufacturing hubs in Shandong, Hebei, and Jiangsu provinces. The aspirin API market was valued at approximately USD 1.68 billion in 2024 and continues to grow at roughly 4% CAGR, driven by aging populations and expanding cardiovascular prophylaxis guidelines in emerging markets. KingWish supplies GMP-certified acetylsalicylic acid meeting USP, EP, and CP standards, supporting pharmaceutical manufacturers worldwide.
| Assay (HPLC, dried basis) | 99.5% - 101.0% (USP/EP) |
|---|---|
| Free Salicylic Acid | ≤ 0.05% (USP); ≤ 0.1% (EP) |
| Loss on Drying | ≤ 0.5% |
| Heavy Metals | ≤ 10 ppm |
| Residual Solvents | Compliant with ICH Q3C; Class 2 solvents ≤ limits |
| GMP Status | Manufactured under ICH Q7 GMP conditions |
Request CoA with HPLC assay data, free salicylic acid content, and residual solvent statement (ICH Q3C). Verify loss on drying and heavy metals. For regulated markets, confirm DMF or CEP filing status.
Elevated free salicylic acid above 0.1% indicates degradation or poor synthesis control. Vinegar-like odor from opened samples suggests moisture exposure and hydrolysis. Vague pharmacopoeia claims without batch-specific data.
Standard: 25 KG/DRUM with inner PE liner. Must be stored at 15-25 degrees Celsius, protected from moisture and light. Ship containers with desiccant. Standard lead time 4-6 weeks depending on regulatory documentation.
Global aspirin API market valued at ~USD 1.68 billion in 2024, growing at ~4% CAGR. China accounts for 60-70% of global production. Demand driven by aging populations and expanding cardiovascular prophylaxis guidelines. Market report